Joint surgery in the Utrecht Rheumatoid Arthritis Cohort: The effect of treatment strategy

Annals of the Rheumatic Diseases

Volumn 65, Issue 11, 2006, Pages 1506-1511

  Verstappen, S M M ^a   Hoes, J N ^a   Ter Borg, E J ^b   Bijlsma, J W J ^a   Blaauw, A A M ^c   Van Ajbada Kuipers, G A ^d   Van Booma Frankfort, C ^e   Jacobs, J W G ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c Flevo Hospital   (Netherlands)

^d MEANDER MEDICAL CENTER   (Netherlands)

^e DEPARTMENT OF SURGERY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; GOLD; HYDROXYCHLOROQUINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; JOINT RADIOGRAPHY; JOINT SURGERY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SURVIVAL TIME; THERAPY DELAY; TREATMENT PLANNING; TREATMENT RESPONSE;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; EPIDEMIOLOGIC METHODS; FEMALE; HUMANS; JOINTS; MALE; MIDDLE AGED; PROGNOSIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33750319854     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2005.049957     Document Type: Article

References (30)

1. Wolfe F, Zwillich SH. The long-term outcomes of rheumatoid arthritis: a 23-year prospective, longitudinal study of total joint replacement and its predictors in 1,600 patients with rheumatoid arthritis. Arthritis Rheum 1998;41:1072-82.
2. James D, Young A, Kulinskaya E, Knight E, Thompson W, Ollier W, et al. Orthopaedic intervention in early rheumatoid arthritis. Occurrence and predictive factors in an inception cohort of 1064 patients followed for 5 years. Rheumatology (Oxford) 2004;43:369-76.
3. Gordon P, West J, Jones H, Gibson T. A 10 year prospective followup of patients with rheumatoid arthritis 1986-96. J Rheumatol 2001;28:2409-15.
4. Cooper NJ. Economic burden of rheumatoid arthritis: a systematic review. Rheumatofogy (Oxford) 2000;39:28-33.
5. Verstappen SM, Verkleij H, Bijlsma JW, Buskens E, Kruize AA, Heurkens AH, et al. Determinants of direct costs in Dutch rheumatoid arthritis patients. Ann Rheum Dis 2004;63:817-24.
6. Lindqvist E, Saxne T, Geborek P, Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. Ann Rheum Dis 2002;61:1055-9.
7. Verstappen SM, Albada-Kuipers GA, Bijlsma JW, Blaauw AA, Schenk Y, Haanen HC, et al. A good response to early DMARD treatment of patients with rheumatoid arthritis in the first year predicts remission during follow-up. Ann Rheum Dis 2004;64:38-43.
8. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
9. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
10. van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM, et al. Aggressive treatment in early rheumatoid arthritis: a randomised controlled trial. On behalf of the Rheumatic Research Foundation Utrecht, The Netherlands. Ann Rheum Dis 2000;59:468-77.
11. Verstappen SM, Jacobs JW, Bijlsma JW, Heurkens AH, Booma-Frankfort C, Borg EJ, et al. Five-year followup of rheumatoid arthritis patients after early treatment with disease-modifying antirheumatic drugs versus treatment according to the pyramid approach in the first year. Arthritis Rheum 2003;48:1797-807.
12. van den Brink HR, van der Heide A, Jacobs JW, van der Veen MJ, Bijlsma JW. Evaluation of the Thompson articular index. J Rheumatol 1993;20:28-32.
13. Bijlsma JW, Oude Heuvel CH, Zaalberg A. Development and validation of the Dutch questionnaire capacities of daily life (VDF) for patients with rheumatoid arthritis. J Rehabil Sci 1990;3:71-4.
14. van der Heijde DM, van Riel PL, Nuver-Zwart IH, Gribnau FW, van de Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet 1989;1:1036-8.
15. Hulsmans HM, Jacobs JW, van der Heijde DM, Albada-Kuipers GA, Schenk Y, Bijlsma JW. The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 2000;43:1927-40.
16. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisofone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
17. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al. Retardation of joint damage in patients with early rheumatoid arthritis by initial aggressive treatment with disease-modifying antirheumatic drugs: five-year experience from the FIN-RACo study. Arthritis Rheum 2004;50:2072-81.
18. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002;46:1443-50.
19. Olsen NJ, Stein CM. New drugs for rheumatoid arthritis. N Engl J Med 2004;350:2167-79.
20. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003;48:35-45.
21. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trial. Lancet 2004;364:263-9.
22. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease-modifying properties, and side effects: a randomized, double-blind, placebo-controlled clinical trial. Ann Intern Med 2002;136:1-12.
23. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. N Engl J Med 1995;333:142-6.
24. Wolfe F, Sharp JT. Radiographic outcome of recent-onset rheumatoid arthritis: a 19-year study of radiographic progression. Arthritis Rheum 1998;41:1571-82.
25. van der Heijde DM, van Riel PL, van Leeuwen MA, van't Hof MA, van Rijswijk MH, van de Putte LB. Prognostic factors for radiographic damage and physical disability in early rheumatoid arthritis. A prospective follow-up study of 147 patients. Br J Rheumatol 1992;31:519-25.
26. Pincus T, Sokka T. Quantitative target values of predictors of mortality in rheumatoid arthritis as possible goals for therapeutic interventions: an alternative approach to remission or ACR20 responses? J Rheumatol 2001;28:1723-34.
27. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48:1530-42.
28. Verstappen SM, Boonen A, Bijlsma JW, Buskens I, Verkleij H, Schenk Y, et al. Working status among Dutch patients with rheumatoid arthritis: work disability and working conditions. Rheumatology (Oxford) 2005;2:202-6.
29. Eberhardt K, Fex E, Johnson U, Wollheim FA. Associations of HLA-DRB and - DQB genes with two and five year outcome in rheumatoid arthritis. Ann Rneum Dis 1996;55:34-9.
30. Crilly A, Maiden N, Capell HA, Madhok R. Genotyping for disease associated HLA DR beta 1 alleles and the need for early joint surgery in rheumatoid arthritis: a quantitative evaluation. Ann Rheum Dis 1999;58:114-17.